Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

August 22, 2017

Study Completion Date

September 20, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

GS-9876

One tablet administered orally once daily

DRUG

Filgotinib

Two tablets administered orally once daily

DRUG

GS-9876 placebo

One tablet administered orally once daily

DRUG

Filgotinib placebo

Two tablets administered orally once daily

DRUG

Methotrexate

Background therapy with methotrexate administered orally or parenterally once weekly

Trial Locations (19)

1233

NMTH Tsar Boris III, Sofia

2068

Medical Center_Clinic of International Institute of clinical Studies, Kyiv

4000

MHAT-Plovdiv AD, Plovdiv

4003

Umhat Kaspela, Plovdiv

16635

Altoona Center for Clinical Research, Duncansville

30114

Medical Associates of North Georgia, Canton

31200

A-Shine s.r.o., Pilsen

32713

Omega Research Consultants, DeBary

34239

Sarasota Arthritis Research Center, Sarasota

42701

Center For Arthritis and Osteoporosis, Elizabethtown

68601

Medical Plus, S.R.O., Uherské Hradiště

77084

Accurate Clinical Management - Najam, Houston

77477

Accurate Clinical Research Inc., Stafford

77598

Medical Center Research LLC, Webster

87102

Albuquerque Center For Rheumatology, Albuquerque

140176

Kharkiv City Hospital 8, Kharkiv

0112

LLC Arensia Exploratory Medicine, T'bilisi

MD-2025

ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital, Chisinau

15-879

ClinicMed Badurski i wspolnicy Spolka Jawna, Bialystok

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY